throbber
ATTORNEYS AT LAW
`WASHINGTON HARBOUR
`3000 K STREET, N.W.
`SUITE 600
`WASHINGTON, D.C. 20007-5109
`202.672.5300 TEL
`202.672.5399 FAX
`foley.com
`
`WRITER’S DIRECT LINE
`608.258.4303
`jmeara@foley.com EMAIL
`
`CLIENT/MATTER NUMBER
`111163-0102
`
`
`
`February 2, 2016
`
`Patent Trial and Appeal Board
`US Patent and Trademark Office
`PO Box 1450
`Alexandria, Virginia 22313-1450
`(electronically filed)
`
`INTER PARTES REVIEW OF U.S. PAT. NO. 8,791,154
`Exhibit Cover Letter Per 37 C.F.R. § 42.6(e)(4)(ii)
`
`
`
`
`Dear Patent Trial and Appeal Board,
`
`This letter incorporates by reference the certificate of service attached to the
`
`end of the Petition for Inter Partes Review filed herewith, to Exhibits 1001-1063, as
`
`listed below:
`
`Exhibit
`Ex. #
`1001 U.S. Patent No. 8,791,154 B2 (“’154 Patent”)
`1002 Declaration of Dr. Erning Xia
`1003 Declaration of Dr. Leonard Bielory
`1004 WO 2008/015695 A2 (“Bhowmick”)
`1005 YANNI et al., “The In Vitro and In Vivo Ocular Pharmacology of
`Olopatadine (AL-4943A), an Effective Anti-Allergic/Antihistaminic
`Agent,” Journal of Ocular Pharmacology and Therapeutics, Volume 12,
`Number 4, 1996, pp. 389-400 (“Yanni”)
`1006 U.S. Pat. No. 6,995,186 B2 (“Castillo”)
`1007 U.S. Pat. Pub. No. 2011/0082145 A1 (“Schneider”)
`
`BOSTON
`BRUSSELS
`CHICAGO
`DETROIT
`
`JACKSONVILLE
`LOS ANGELES
`MADISON
`MIAMI
`
`MILWAUKEE
`NEW YORK
`ORLANDO
`SACRAMENTO
`
`SAN DIEGO
`SAN DIEGO/DEL MAR
`SAN FRANCISCO
`SHANGHAI
`
`SILICON VALLEY
`TALLAHASSEE
`TAMPA
`TOKYO
`WASHINGTON, D.C.
`
`4837-5701-8669.1
`
`

`
`FOLEY & L ARDN ER LLP
`February 2, 2016
`Page 2
`
`1008 U.S. Pat. No. 5,641,805 B2(“Hayakawa”)
`1009
`Image File Wrapper for U.S. Patent No. 8,791,154 B2
`1010
`Image File Wrapper for U.S. Provisional Appl. No. 61/487,789
`1011
`Image File Wrapper for U.S. Provisional Appl. No. 61/548,957
`1012 WO 1999/018963 (“Lisi”)
`1013 WO 2002/024116 A1 (“Shahinian”)
`LOFTSSON et al., “Cyclodextrins in eye drop formulations: enhanced
`1014
`topical delivery of corticosteroids to the eye,” Acta Ophthamologica
`Scandinavica, 2002, pp. 144-150.
`1015 NANDI et al., “Synergistic Effect of PEG-400 and Cyclodextrin to
`Enhance Solubility of Progesterone,” AAPS PharmSciTech 2003; 4 (1),
`pp 1-5.
`1016 WO 2011/138801 A1 (“Khopade”)
`JANSOOK et al., “CDs as solubilizers: Effects of excipients and
`1017
`competing drugs,” International Journal of Pharmaceutics, 379, 2009,
`pp. 32-40.
`1018 HARADA, A., “Preparation and structures of supramolecules between
`cyclodextrins and polymers,” Coordination Chemistry Reviews, 148,
`1996, pp. 115-133.
`1019 WO 2012/159064A1 (“Gamache”)
`1020
`EP 0 799 044 B1 (“Yanni III”)
`1021 WO 2001/054687 A1 (“Yanni II”)
`1022 WO 2009/003199 A1 (“Pipkin”)
`1023 WO 2000/78396 A2 (“Graff”)
`1024 Curriculum Vitae for Dr. Erning Xia
`1025 Curriculum Vitae for Dr. Leonard Bielory
`1026 U.S. Pat. No. 7,687,646 B2 (“Bader”)
`1027 U.S. Pat. No. 4,871,865 (“Lever”)
`
`4837-5701-8669.1
`
`

`
`FOLEY & L ARDN ER LLP
`February 2, 2016
`Page 3
`
`1028 U.S. Pat. No. 5,116,863 (“Oshima”)
`1029
`EP 0214779 B1 (“Lever”)
`1030 Alcon Research, Ltd. v. Apotex Inc., 687 F.3d 1362 (Fed. Cir. 2012)
`1031 Alcon Research, Ltd. v. Apotex Inc., 790 F. Supp. 2d 868 (S.D. Ind.
`2011)
`EP 0 235 796 B2 (“Oshima”)
`1032
`1033 ABELSON et al., “Combined Analysis of Two Studies Using the
`Conjunctival Allergen Challenge Model to Evaluate Olopatadine
`Hydrochloride, a New Ophthalmic Antiallergic Agent With Dual
`Activity,” American Journal of Ophthalmology, Volume 126, No. 6, pp.
`797-804.
`1034 WO 2004/024126 A1 (“Thompson”)
`1035 CHAUDHARI et al., “Solubility enhancement of hydrophobic drugs
`using synergistically interacting cyclodextrins and cosolvent,” Current
`Science, 1586 Vol. 92, No. 11, 10 June 2007; pp. 1586-1591.
`1036 ANSEL, Howard C., Pharmaceutical Calculations, 13th Ed., Wolters
`Kluwer, 2010, pp. 82-83
`PATANOL® Label
`1037
`PATADAY® Label
`1038
`PATANASE® Label
`1039
`1040 GENNARO, Alfonso R., Remington: The Science and Practice of
`Pharmacy, Philadelphia College of Pharmacy and Science, 1995, Vol.
`1., pp. 613-627
`1041 GENNARO, Alfonso R., Remington: The Science and Practice of
`Pharmacy, Philadelphia College of Pharmacy and Science, 1995, Vol.
`2., pp. 1563-1576
`LIDE, David R., CRC Handbook of Chemistry and Physics, CRC Press,
`2006, pp. 6-4 – 6-5.
`1043 ABELSON and ANDERSON, “Demystifying Dumulcents,” Review of
`Ophthalmology, November 2006, pp. 122-125.
`
`1042
`
`4837-5701-8669.1
`
`

`
`FOLEY & L ARDN ER LLP
`February 2, 2016
`Page 4
`
`1044
`
`LOFTSSON, et al., “The effect of water-soluble polymers on the
`aqueous solubility and complexing abilities of β-cyclodextrin,”
`International Journal of Pharmaceutics, 1998, Vol. 163, pp. 15-21
`1045 U.S. Patent Publication US 2009/0156568 A1 (“Hughes”)
`1046 U.S. Pat. No. 5,985,310 (“Castillo III”)
`1047 U.S. Pat. No. 7,977,376 B2 (“Singh I”)
`1048 U.S. Pat. No. 8,399,508 B2 (“Singh II”)
`1049 U.S. Pat. No. 7,402,609 B2 (“Castillo II”)
`1050 WADE, et al., “Ophthalmic antihistamines and H1–H4 receptors,”
`Current Opinion in Allergy and Clinical Immunology, 2012, Vol. 12,
`No. 5, pp. 510–516
`1051 CHOI, et al., “Late-phase reaction in ocular allergy,” Current Opinion in
`Allergy and Clinical Immunology, 2008, Vol 8, pp. 438–444.
`1052 U.S. Pat. Pub. 2004/0198828 (“Abelson 2004”)
`LEONARDI, et al., “Double-masked, randomized, placebo-controlled
`1053
`clinical study of the mast cell-stabilizing effects of treatment with
`olopatadine in the conjunctival allergen challenge model in humans,”
`Clin Ther 2003; 25, pp. 2539–2552.
`PROUD, et al., “Inflammatory mediator release on conjunctival
`provocation of allergic subjects with allergent provocation of allergic
`subjects with allergen,” Mediator generation in ocular allergy, 1989,
`Vol. 85. No. 5, pp. 896-905
`SHARIF, et al., “Characterization of the Ocular Antiallergic and
`Antihistaminic Effects of Olopatadine (AL-4943A), a Novel Drug for
`Treating Ocular Allergic Diseases,” The Journal OF Pharmacology and
`Experimental Therapeutics, 1996, Vol. 278, No. 3, pp. 1252-1261
`LOFTSSON, et al., “Pharmaceutical Applications of Cyclodextrins. 1.
`Drug Solubilization and Stabilization,” Journal of Pharmaceutical
`Sciences, October 1996, Vol. 85, No. 10, pp. 1017-1025
`21 C.F.R. §349.12
`Polyvinylpyrrolidone K 30,
`
`1057
`1058
`
`1054
`
`1055
`
`1056
`
`4837-5701-8669.1
`
`

`
`FOLEY & L ARDN ER LLP
`February 2, 2016
`Page 5
`
`1059
`
`http://www4.mpbio.com/ecom/docs/proddata.nsf/(webtds2)/102787
`SWEI, et al., “Viscosity Correlation for Aqueous Polyvinylpyrrolidone
`(PVP) Solutions,” Journal of Applied Polymer Science, 2003, Vol. 90,
`pp. 1153-1155
`68 Fed. Reg. 106, 32981-32983
`1060
`1061 U.S. Pat. No. 6,316,483 B1 (“Haslwanter”)
`1062 U.S. Pat. Pub. No. 2010/0010082 A1 (“Chong”)
`1063 U.S. Pat. Pub. No. 2009/0136598 (“Chapin”)
`
`
`The Commissioner is hereby authorized to charge any additional fees which
`
`may be required regarding this Application under 37 C.F.R. §§ 1.16-1.17, or credit
`
`any overpayment, to Deposit Account No. 19-0741. Should no proper payment be
`
`enclosed herewith, as by the credit card payment instructions in EFS-Web being
`
`incorrect or absent, resulting in a rejected or incorrect credit card transaction, the
`
`Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-
`
`0741. If any extensions of time are needed for timely acceptance of papers submitted
`
`herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and
`
`authorizes payment of any such extensions fees to Deposit Account No. 19-0741.
`
`4837-5701-8669.1
`
`

`
`4837-5701-8669.1
`
`Best regards,
`
`
`
`/Joseph P. Meara/
`
`Joseph P. Meara
`Registration No. 44,932
`
`FOLEY & L ARDN ER LLP
`February 2, 2016
`Page 6
`
`

`
`FOLEY & L ARDN ER LLP
`February 2, 2016
`Page 7
`
`CERTIFICATE OF SERVICE
`
`
`The undersigned hereby certifies that a copy of the foregoing cover letter was
`
`served on February 2, 2016 by placing a copy into USPS Express Mail directed to the
`
`attorney of record for the patent at the following address:
`
`ALCON
`IP LEGAL
`6201 SOUTH FREEWAY
`FORT WORTH TX 76134
`
`
`
`
`By: /Joseph P. Meara/
`Joseph P. Meara
`Registration No. 44,932
`Counsel for Petitioner
`
`
`4837-5701-8669.1

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket